Trials / Conditions / Recurrent NSCLC
Recurrent NSCLC
6 registered clinical trials studyying Recurrent NSCLC — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Unknown | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC NCT04846452 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Active Not Recruiting | Phase 2 Study of Dacomitinib in NSCLC NCT04027647 | National Cancer Centre, Singapore | Phase 2 |
| Unknown | Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NS NCT00813332 | Simcere Pharmaceutical Co., Ltd | Phase 4 |